Repligen Corporation (RGEN): Price and Financial Metrics


Repligen Corporation (RGEN): $165.88

5.55 (+3.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RGEN POWR Grades


  • RGEN scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.7% of US stocks.
  • The strongest trend for RGEN is in Momentum, which has been heading down over the past 179 days.
  • RGEN ranks lowest in Momentum; there it ranks in the 14th percentile.

RGEN Stock Summary

  • With a price/earnings ratio of 79.49, Repligen Corp P/E ratio is greater than that of about 91.2% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Repligen Corp is higher than 94.37% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 15.21, Repligen Corp has a higher such ratio than 90.67% of stocks in our set.
  • Stocks that are quantitatively similar to RGEN, based on their financial statements, market capitalization, and price volatility, are MLAB, ICHR, LUNG, OMCL, and NVRO.
  • RGEN's SEC filings can be seen here. And to visit Repligen Corp's official web site, go to www.repligen.com.

RGEN Valuation Summary

  • RGEN's EV/EBIT ratio is 123.6; this is 321.84% higher than that of the median Healthcare stock.
  • Over the past 243 months, RGEN's price/sales ratio has gone down 6.
  • RGEN's price/earnings ratio has moved up 167.9 over the prior 243 months.

Below are key valuation metrics over time for RGEN.

Stock Date P/S P/B P/E EV/EBIT
RGEN 2021-08-31 30.6 9.7 155.7 123.6
RGEN 2021-08-30 30.6 9.7 155.6 123.6
RGEN 2021-08-27 29.8 9.5 151.7 120.4
RGEN 2021-08-26 29.5 9.4 150.0 119.0
RGEN 2021-08-25 29.6 9.4 150.7 119.6
RGEN 2021-08-24 29.2 9.3 148.7 117.9

RGEN Growth Metrics

    The 2 year revenue growth rate now stands at 83.76%.
  • The 3 year cash and equivalents growth rate now stands at 265.49%.
  • Its 2 year net income to common stockholders growth rate is now at -19.35%.
Over the past 34 months, RGEN's revenue has gone up $460,698,000.

The table below shows RGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 670.534 119.016 128.291
2021-09-30 592.661 84.267 118.879
2021-06-30 508.505 83.273 99.933
2021-03-31 433.007 62.357 79.561
2020-12-31 366.26 62.625 59.926
2020-09-30 327.086 65.428 43.832

RGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGEN has a Quality Grade of C, ranking ahead of 39.46% of graded US stocks.
  • RGEN's asset turnover comes in at 0.293 -- ranking 157th of 682 Pharmaceutical Products stocks.
  • ORMP, MESO, and AWH are the stocks whose asset turnover ratios are most correlated with RGEN.

The table below shows RGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.293 0.586 0.452
2021-06-30 0.278 0.588 0.369
2021-03-31 0.257 0.574 0.269
2020-12-31 0.235 0.572 0.186
2020-09-30 0.229 0.576 0.144
2020-06-30 0.215 0.569 0.109

RGEN Price Target

For more insight on analysts targets of RGEN, see our RGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $267.88 Average Broker Recommendation 1.35 (Strong Buy)

RGEN Stock Price Chart Interactive Chart >

Price chart for RGEN

RGEN Price/Volume Stats

Current price $165.88 52-week high $327.32
Prev. close $160.33 52-week low $137.21
Day low $160.71 Volume 776,900
Day high $166.41 Avg. volume 505,262
50-day MA $154.83 Dividend yield N/A
200-day MA $214.96 Market Cap 9.03B

Repligen Corporation (RGEN) Company Bio


Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.


RGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

RGEN Latest Social Stream


Loading social stream, please wait...

View Full RGEN Social Stream

Latest RGEN News From Around the Web

Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Yahoo | February 18, 2022

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Yahoo | February 18, 2022

Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call Transcript

Repligen Corporation (RGEN) Q4 2021 Earnings Conference Call February 17, 2021 8:30 am ET Company Participants Tony Hunt - President, Chief Executive Officer Jon Snodgres - Chief Financial Officer Sondra Newman - Head of Investor Relations Conference Call Participants Dan Arias - Stifel Jacob Johnson - Stephens Julia Qin -...

SA Transcripts on Seeking Alpha | February 17, 2022

Repligen''s Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance

Repligen Corp (NASDAQ: RGEN ) reported Q4 FY21 sales of $186.5 million , up 72% Y/Y as reported and 73% at constant currency, with organic growth of 69%, beating the consensus of $179.29 million. The base business accounted for 64% of revenue, COVID-related sales accounted for 33% of revenue, and … Full story available on Benzinga.com

Benzinga | February 17, 2022

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

GlobeNewswire | February 17, 2022

Read More 'RGEN' Stories Here

RGEN Price Returns

1-mo -2.45%
3-mo -10.00%
6-mo -35.68%
1-year -13.43%
3-year 93.00%
5-year 298.75%
YTD -37.37%
2021 38.20%
2020 107.17%
2019 75.39%
2018 45.37%
2017 17.72%

Continue Researching RGEN

Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:

Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6155 seconds.